EpiVax and CUBRC Awarded FDA Contract Worth $2M for Development of Control Peptides for Immunogenicity Risk Assessment Assays Supporting Regulatory Filings of Generic Peptide Drugs

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

EpiVax-CUBRC-Awarded

More Like This

PR Newswire associated0

EpiVax and FDA Scientists Publish New Insights on Immunogenicity Risks of Peptide-Related Impurities in Generic Teriparatide

PR Newswire associated0

EpiVax Drives Immunogenicity Innovation in 2024: Year in Review

PR Newswire associated0

EpiVax Announces Laboratory Expansion and Streamlined, NAM-Centric In Vitro Services

PR Newswire associated0

EpiVax Strengthens Technology Leadership Amid Immunoinformatics Advancements

Business Wire logo

ViiV Healthcare to present data for its next generation of ultra long-acting treatments for HIV

Intravacc Secures French CIR Approval to Support Vaccine R&D Partnerships

ViiV Healthcare extends voluntary licensing agreement with Medicines Patent Pool to enable access to innovative long-acting injectable HIV treatment

PR Newswire associated0

Novel Immunogenicity Risk Assessment Platform, ISPRI, Facilitates Biologic Therapeutics Development